Peter Deen is a molecular cell physiologist interested in the (patho)physiology of integrative and renal water homeostasis regulation and energy metabolism in health and disease. His team was the first to identify mutations in the AQP2 gene, leading to Nephrogenic Diabetes Insipidus (NDI), a disease in which humans cannot concentrate their urine and consequently void 10-15 liters of urine daily. His team deciphered the underlying mechanisms of recessive and dominant NDI. At present, his research focuses on the understanding the etiology and treatment and development of improved treatment for NDI and chronic kidney disease (CKD) induced by lithium. Lithium is the main treatment for bipolar disorders and is the most common form of NDI. Besides, he investigates the role of the succinate receptor (SUCNR1) in health and disease. The mitochondrial metabolite succinate is released from cell when under metabolic stress and it has only recently been identified that it can bind and activate a plasma receptor, SUCNR1. The role of the SUCNR1 is investigated in common metabolic disorders, such as diabetes type-II, age-related macular degeneration, CKD and paraganglioma’s (adrenal cancer). For his research, he obtained a KNAW fellowship, was the first European recipient of the prestigious Young Investigator Award of the American Physiological Society in 2001, and obtained a prestigious VICI grant in 2007. In May 2010, he was promoted to full professor in Cellular Physiology.
Peter Deen is a full professor at the department of Physiology.
<< go back